DLBCL
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.
News
FDA panel voices concerns over 2 lymphoma accelerated approvals
FDA’s ODAC committee pressed for resolution on whether 2 lymphoma drugs, long on the U.S. market, actually deliver significant benefits to...
Conference Coverage
FDA’s Project Optimus aims to transform early cancer research
Q & A with an expert on how the FDA’s Project Optimus targets toxicity and how it could spell the end of traditional dose-escalation trials....
Conference Coverage
DLBCL treatment options: CAR T outperforms ASCT
Relapsed and refractory DLBCL patients treated with CAR T-cell therapy achieved better outcomes than with autologous stem cell transplants.
Conference Coverage
When to treat DLBCL with radiotherapy?
Choices depend on factors like evidence of disease, radiologists say.
Conference Coverage
Safely skip PET2 after brentuximab in Hodgkin lymphoma?
Recent data presented at SOHO 2023 suggested that adding brentuximab vedotin to chemotherapy for Hodgkin lymphoma improves outcomes, even without...
From the Journals
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
Conference Coverage
Huge underuse of germline testing for cancer patients
Information from germline genetic testing could affect a patient’s cancer care.
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.